Cellular Biomedicine Group, Inc. Featured on Wide World of Stocks Television
January 15 2015 - 9:28AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced that the interview with Dr. William (Wei) Cao, Chief
Executive Officer of Cellular Biomedicine Group, will be broadcast
on Wide World of Stocks today, Thursday, January 15, at 5:00 p.m.
and 6:00 p.m. EST into more than 50 million homes nationwide over
BizTV, BizTV Radio, and Youtoo America Networks.
In the interview, Dr. Cao provides insight into the company's
recent successes from its Phase I/IIa clinical trial for Rejoin™
human adipose-derived mesenchymal progenitor cell (haMPC)
regenerative therapy for Knee Osteoarthritis (KOA), and other
clinical progress, as well as strengthening the Company's already
impressive IP portfolio, including the build-out of its immune cell
therapy platform focused on oncology. "It was a pleasure to present
Cellular Biomedicine Group's compelling value proposition. We are
looking forward to continued progress in our clinical trials and
communicating this information to our shareholders and partners,"
said Dr. Cao.
WWOS' interview with Cellular Biomedicine Group can be seen
nationwide today on BizTv at 5:00pm EST and on Youtoo America
(formally America One Network) at 6:00pm EST.
Find us in your market: http://www.filmon.com/channel/biztv
http://www.americaone.com/watch/ https://www.youtoo.com/ Wide World
of Stocks YouTube
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
About Wide World of Stocks
Wide World of Stocks delivers visibility to companies in the
small-cap sector. Wide World of Stocks offers a complete
multi-level awareness package that provides valuable exposure for
your company, products and services. Wide World of Stocks is a
print and digital content provider with multi-channel integration
including television, webcasts, podcasts and a magazine in both
digital and print formats. WWOS has been seen in 100+ million
homes, regionally and nationally on cable and major networks
including CBS, NBC, ABC, and FOX. For more information visit
www.wideworldofstocks.com. Wide World of Stocks is owned and
published by Valhalla Venture Group, LLC. Learn more at
www.wideworldofstocks.com.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024